Charles River Laboratories International, Inc. (CRL)

198.15 -10.48 (-5.02%) At close: 04:00PM EDT

Charles River Laboratories International, Inc.

251 Ballardvale Street
Wilmington, MA 01887
United States
781 222 6000
https://www.criver.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 20,000

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James C. Foster J.D.	Chairman, CEO & Pres	2.51M	6.13M	1951
Ms. Flavia H. Pease	Corp. Exec. VP & CFO	772.4k	N/A	1973
Ms. Birgit Girshick	Corp. Exec. VP & COO	1.15M	N/A	1970
Mr. Joseph W. LaPlume	Corp. Exec. VP of Corp. Devel. & Strategy	871.35k	887.84k	1974
Mr. William D. Barbo	Chief Commercial Officer & Corp. Exec. VP	928.55k	354.38k	1961
Mr. Michael Gunnar Knell	Corp. Sr. VP & Chief Accounting Officer	N/A	N/A	1977
Prof. Julie Frearson Ph.D.	Corp. Sr. VP & Chief Scientific Officer	N/A	N/A	N/A
Mr. Mark Mintz	Corp. Sr. VP & Chief Information Officer	N/A	N/A	N/A
Todd Spencer	Corp. VP of Investor Relations	N/A	N/A	N/A
Mr. Matthew L. Daniel	Corp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Corporate governance

Charles River Laboratories International, Inc.’s ISS governance QualityScore as of 1 September 2023 is 7. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.